Oramed Pharmaceuticals buy me8
Start price
30.11.20
/
50%
€6.18
Target price
30.11.21
€8.00
Performance (%)
-22.65%
End price
30.11.20
€4.78
Summary
This prediction ended on 30.11.20 with a price of €4.78. The prediction for Oramed Pharmaceuticals disappointed with a performance of -22.65%. me8 has 50% into this predictionOramed is a pharmaceutical company that focuses on the development of innovative oral delivery solutions for drugs that are traditionally administered through injection. The company is primarily dedicated to the development of an oral insulin capsule that can potentially revolutionize the treatment of diabetes. Their flagship product, ORMD-0801, is currently in Phase III clinical trials in the United States and has received Fast Track designation from the FDA. Oramed is a publicly traded company listed on the Nasdaq under the ticker symbol ORMP.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Oramed Pharmaceuticals | -2.649% | -2.649% | 5.251% | -72.710% |
| iShares Core DAX® | 2.112% | -0.367% | 13.466% | 16.854% |
| iShares Nasdaq 100 | -2.197% | -3.794% | 38.426% | 42.934% |
| iShares Nikkei 225® | -1.555% | -7.320% | 18.451% | 2.941% |
| iShares S&P 500 | -0.472% | -2.078% | 27.488% | 41.955% |
According to me8 what are the pros and cons of Oramed Pharmaceuticals for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Fair valuation
Capable Management
Top 10 in its market
Cons
Risky balance sheet
No uniques
Little known brand
Comments by me8 for this prediction
In the thread Oramed Pharmaceuticals diskutieren
Buy Oramed Pharmaceuticals
Kursziel gesetzt auf 8,0